Compare AbbVie Inc (ABBV) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? AbbVie Inc trades at $249.94 (market cap $441.94B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $61.49 (market cap $78.85B). The key difference: AbbVie Inc is far larger — about 5.6× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| ABBV | MDLZ | |
|---|---|---|
Market Cap | $441.94B | $78.85B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $64.99 |
52-Week Low | $197.38 | $51.51 |
Enterprise Value | $506.19B | $99.19B |
Dividend Yield | 2.77% | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
MDLZ trades at $61.53, down 1.72% today, with a bullish technical outlook supported by moving averages and oversold RSI signals. The company reported strong Q2 2026 earnings, beating estimates with $0.73 EPS and raising organic sales guidance, driven by growth in emerging markets. Valuation ratios like P/E of 37.75 and P/S of 4.01 reflect premium pricing, while profitability remains solid with an 8.86% net income margin.
The stock offers upside to the $70.50 consensus price target, supported by analyst optimism and institutional buying, but faces risks from reliance on international sales and margin pressures. Earnings momentum and dividend stability provide a favorable outlook, though macroeconomic volatility could challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
